Heron Therapeutics (NASDAQ:HRTX) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a buy rating in a research report report published on Wednesday.

Separately, Needham & Company LLC cut their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday.

Heron Therapeutics Trading Down 4.0 %

Shares of Heron Therapeutics stock opened at $1.19 on Wednesday. The stock has a market capitalization of $180.99 million, a price-to-earnings ratio of -6.61 and a beta of 1.81. Heron Therapeutics has a twelve month low of $0.81 and a twelve month high of $3.93. The business’s 50 day simple moving average is $1.82 and its 200-day simple moving average is $2.51.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter in the previous year, the company earned ($0.17) earnings per share. Sell-side analysts predict that Heron Therapeutics will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new stake in Heron Therapeutics in the second quarter worth about $27,000. HB Wealth Management LLC acquired a new stake in shares of Heron Therapeutics in the 2nd quarter worth approximately $35,000. Headlands Technologies LLC bought a new position in shares of Heron Therapeutics in the first quarter valued at approximately $30,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics in the second quarter valued at approximately $41,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Heron Therapeutics during the first quarter valued at approximately $32,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.